Overview

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Status:
Completed
Trial end date:
2018-10-18
Target enrollment:
0
Participant gender:
All
Summary
To assess the safety of intravitreal Zimura™ (complement factor C5 inhibitor) administered in combination with Lucentis® 0.5 mg in treatment naïve subjects with neovascular age related macular degeneration (NVAMD)
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ophthotech Corporation
Treatments:
Ranibizumab
Criteria
Inclusion Criteria:

- Active subfoveal NVAMD

Exclusion Criteria:

- History or evidence of severe cardiac disease

- Any major surgical procedure within one month of trial entry

- Subjects with a clinically significant laboratory value

- Any treatment with an investigational agent in the past 60 days for any condition

- Women who are pregnant or nursing

- Known serious allergies to the fluorescein dye used in angiography, povidone iodine,
to the components of the ranibizumab formulation, or to the components of the Zimura
formulation

- Any prior treatment for AMD other than oral supplements of vitamins and minerals